Enfoque «Treat to target» en el tratamiento de la enfermedad inflamatoria intestinal

Paulina Nuñez F*, Uma Mahadevan, Rodrigo Quera, Constanza Bay, Patricio Ibañez

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

3 Citas (Scopus)

Resumen

With the advent of biologic and small molecule therapies, there has been a substantial change in the treatment of inflammatory bowel disease. These advances have had a great impact in preventing disease progression, intestinal damage and, therefore, have contributed to a better quality of life. Discordance between symptom control and mucosal healing has been demonstrated. This has led to the search for new disease control targets. The treat to target strategy, based on expert recommendations and now a randomized controlled trial, has determined that clinical and endoscopic remission should be the goal of therapy. Biomarkers (fecal calprotectin) can be a surrogate target. Although histological healing has shown benefits, there is inadequate evidence and inadequate therapy for that to be a fixed goal at this time. This review will focus on therapeutic goals, according to the evidence currently available, and evaluate strategies to achieve them.

Título traducido de la contribuciónTreat-to-target approach in the management of inflammatory Bowel disease
Idioma originalEspañol
Páginas (desde-hasta)312-319
Número de páginas8
PublicaciónGastroenterologia y Hepatologia
Volumen44
N.º4
DOI
EstadoPublicada - abr 2021
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2020 Elsevier España, S.L.U.

Palabras clave

  • Biomarkers
  • Crohn's disease
  • Monitoring
  • Treat-to-target
  • Ulcerative colitis

Huella

Profundice en los temas de investigación de 'Enfoque «Treat to target» en el tratamiento de la enfermedad inflamatoria intestinal'. En conjunto forman una huella única.

Citar esto